NCCN Guidelines for Patients® | Myeloproliferative Neoplasms

48 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms, 2018 Allogeneic HCT Allogeneic HCT ( h ematopoietic c ell t ransplant) is an option for INT-2- and high-risk MF. It may also be an option for INT-1 if platelets are low and complex cytogenetics are present. It provides the only chance for a cure. However, it is not safe for everyone. Most people will not be able to undergo allogeneic HCT. Your doctor will assess if a transplant is right for you. He or she will consider your age, health, preference, and other factors. For PMF, higher- risk gene mutations may be considered. Such mutations, including ASXL1 , increase the chance for acute leukemia. If present, your doctor may advise undergoing an allogeneic transplant. Anemia treatment Many people with MF have anemia. Anemia is a condition of low red blood cells or hemoglobin. See Figure 12 . Treatment for anemia is described in the next section. For INT-2 and high-risk MF, treatment for anemia may be the main type of care you will receive. It is an option if you can’t have an allogeneic HCT and you don’t have other symptoms. 5 Myelofibrosis Initial treatment Figure 12 Anemia Many people with MF have anemia. Anemia is a health condition of low red blood cells or hemoglobin.

RkJQdWJsaXNoZXIy MTE3MTE1